Program
denifanstat
Also written as “Denifanstat”, “ASC40” and “TVB-2640”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Acne Vulgaris · Glioblastoma · Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sagimet Biosciences | 91 open or running | phase 3since Sep 10, 2024 | Aug 18, 2014 | Aug 2027phase 3 · NCT07863193 |
| Ascletis Pharma | 61 open or running | phase 3since Oct 26, 2021 | Apr 14, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 18, 2014First study: phase 1 study in NeoplasmsNew to Sagimet BiosciencesSagimet Biosciences · NCT02223247 · 180 enrolled · United States, United Kingdom
- Apr 24, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseSagimet Biosciences · NCT03938246 · 142 enrolled · United States, China
- Apr 14, 2020Ascletis Pharma's first study: phase 1 study in HealthyNew to Ascletis PharmaAscletis Pharma · NCT04352361 · 34 enrolled · China
- Apr 9, 2021Phase 1 study in HealthyAscletis Pharma · NCT04843449 · 24 enrolled · China
- May 20, 2021Phase 2 study in Non-alcoholic Fatty Liver DiseaseSagimet Biosciences · NCT04906421 · 168 enrolled · United States, Canada, Poland and more
- Oct 26, 2021Phase 3 study in GlioblastomaAscletis Pharma · NCT05118776 · 136 enrolled · China
- Oct 26, 2021Phase 2 study in Acne VulgarisAscletis Pharma · NCT05104125 · 180 enrolled · China
- Dec 12, 2022Phase 1 study in Healthy VolunteersSagimet Biosciences · NCT05657834 · 8 enrolled · United States
- Apr 17, 2023Phase 1 study in Non-alcoholic Fatty Liver DiseaseSagimet Biosciences · NCT05835180 · 48 enrolled · United States, Hungary
- Dec 14, 2023Phase 3 study in Acne VulgarisAscletis Pharma · NCT06192264 · 480 enrolled · China
- Jan 31, 2024Phase 3 study in Acne VulgarisAscletis Pharma · NCT06248008 · 240 enrolled · China
- Sep 10, 20242 phase 3 studies in Non-alcoholic Fatty Liver DiseaseSagimet Biosciences · NCT06692283, NCT06594523
- Oct 8, 2025Phase 1 study in HealthySagimet Biosciences · NCT07216313 · 40 enrolled · United States
- Oct 2, 2026Phase 3 study in Acne VulgarisSagimet Biosciences · NCT07863193 · 800 planned · United States
Ahead
- Aug 2027Primary completion: phase 3 study in Acne VulgarisSagimet Biosciences · NCT07863193
TargetBeta
“An orally bioavailable fatty acid synthase (FASN) inhibitor, ”NCIt, by rule
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07863193Acne Vulgaris · United States | 3 | Recruiting | Sagimet Biosciences | Aug 2027 | 800 |
| NCT07216313Healthy · United States | 1 | Completed | Sagimet Biosciences | Oct 20, 2025 | 40 |
| NCT06692283Non-alcoholic Fatty Liver Disease | 3 | Withdrawn | Sagimet Biosciences | Jun 2026 | 0 |
| NCT06594523Non-alcoholic Fatty Liver Disease | 3 | Withdrawn | Sagimet Biosciences | Dec 2030 | 0 |
| NCT06248008Acne Vulgaris · China | 3 | Completed | Ascletis Pharma | Nov 12, 2025 | 240 |
| NCT06192264Acne Vulgaris · China | 3 | Completed | Ascletis Pharma | May 19, 2025 | 480 |
| NCT05835180Non-alcoholic Fatty Liver Disease · United States, Hungary | 1 | Completed | Sagimet Biosciences | Dec 18, 2023 | 48 |
| NCT05657834Healthy Volunteers · United States | 1 | Completed | Sagimet Biosciences | Dec 21, 2022 | 8 |
| NCT05118776Glioblastoma · China | 3 | Active, not recruiting | Ascletis Pharma | Jun 2025 | 136 |
| NCT05104125Acne Vulgaris · China | 2 | Completed | Ascletis Pharma | Apr 10, 2023 | 180 |
| NCT04906421Non-alcoholic Fatty Liver Disease · United States, Canada, Poland and more | 2 | Completed | Sagimet Biosciences | Oct 2, 2023 | 168 |
| NCT04843449Healthy · China | 1 | Completed | Ascletis Pharma | May 6, 2021 | 24 |
| NCT04352361Healthy · China | 1 | Completed | Ascletis Pharma | Apr 29, 2020 | 34 |
| NCT03938246Non-alcoholic Fatty Liver Disease · United States, China | 2 | Completed | Sagimet Biosciences | Oct 2, 2021 | 142 |
| NCT02223247Neoplasms · United States, United Kingdom | 1 | Completed | Sagimet Biosciences | Jun 2017 | 180 |
How it is read
Names in the registry
- “Denifanstat”, 3 entries
- “ASC40”, 3 entries
- “TVB-2640”, 3 entries
- “ASC40 25mg”, 1 entry
- “ASC40 50mg”, 1 entry
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 5 studies
- Acne Vulgaris, 4 studies
- Glioblastoma, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.